Determining the Optimal Adenosine Provocation Test (impact)
Primary Purpose
Asthma
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Bronchial provocation test
Sponsored by

About this trial
This is an interventional diagnostic trial for Asthma focused on measuring asthma, small airways disease, inflammation, provocation, adenosine
Eligibility Criteria
Inclusion Criteria:
- A doctor's diagnosis of asthma
- Age: 18-65 years
- PC20 AMP < 320 mg/ml
- Non-smoker
- Steroid naive or steroids have been stopped 4 weeks before entry into the baseline period
Exclusion Criteria:
- Recent exacerbation asthma (<2 months) or upper respiration tract infection (<2 weeks)
- Severe airway obstruction at baseline, FEV1pred< 50% or < 1.2L
- Diagnosis of COPD or any other pulmonary disease that could influence the study results as judged by the investigator
- Pregnancy or lactating women. (i.e. women of childbearing potential who do not use adequate anticonception as judged by the investigator).
Sites / Locations
- University Medical Center Groningen
- University Medical Center Groningen
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
bronchial provocationtest
Arm Description
Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
Outcomes
Primary Outcome Measures
The small airway reaction to provocation with adenosine, reflected by the IOS parameter R5-R20
The R5-R20 is measured with the IOS. This a method to determine the resistance of the small airways. The R5-R20 is measured during each provocation test after each provocative step.
Secondary Outcome Measures
The total airway reaction to provocation with adenosine, reflected by the decline in FEV1 (PD20/ PC20 values)
We want to compare the different PD20/PC20 values of the three dry powder adenosine provocation test and with the nebulized AMP provocation test. The lung function is measured after each provocative step to determine the point of 20% decline in FEV1. The provocation test is ended after the last step or is ended prematurely when there is a 20% fall of FEV1 compared to baseline
Full Information
NCT ID
NCT01610921
First Posted
May 22, 2012
Last Updated
July 10, 2014
Sponsor
University Medical Center Groningen
Collaborators
Chiesi Farmaceutici S.p.A.
1. Study Identification
Unique Protocol Identification Number
NCT01610921
Brief Title
Determining the Optimal Adenosine Provocation Test
Acronym
impact
Official Title
Determining the Optimal Dry Powder Adenosine Provocation Test to Assess Small Airways Disease
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
May 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Center Groningen
Collaborators
Chiesi Farmaceutici S.p.A.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Asthma is a frequently occurring inflammatory lung disease that affects the whole bronchial tree including the small airways (<2mm). Since the introduction of the solution hydrofluoroalkane (HFA) technology it is possible to generate medication with small particles of approximately 1-2 μm, and therefore to reach the small airways. However, at this moment the investigators have no reliable instruments to identify the asthmatic subjects who particularly benefit from treatment with inhaled small particles. Recently the investigators research group investigated whether provocation with small and large particles AMP is able to identify responders and non-responders to treatment with small and large particles of inhaled corticosteroids. This provocation technique gave promising results but needs further optimization.
The aim of this study is to determine the optimal particle size of dry powder adenosine to assess small airway involvement in asthma. Secondary, to provide insight in the associations between the standard test, executed with nebulized AMP, and the new test, executed with dry powder Adenosine.
Detailed Description
This is a cross-over study. The study population consists of 10 non-smoking asthma patients in the age of 18-65 years who have a PC20 metacholine value ≤4.9mg/ml.
Participating subjects perform 6 provocation tests in randomized order: one test with nebulized methacholine, one test with nebulized AMP, four times dry powder adenosine provocation test. (small particles with inhaled with a slow flow, small particles inhaled with a fast flow, large particles inhaled with a slow flow, large particles inhaled with a fast flow)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
asthma, small airways disease, inflammation, provocation, adenosine
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
N/A
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
bronchial provocationtest
Arm Type
Experimental
Arm Description
Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
Intervention Type
Other
Intervention Name(s)
Bronchial provocation test
Other Intervention Name(s)
bronchial challenge test, AMP test, adenosine bronchial provocation
Intervention Description
Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
Primary Outcome Measure Information:
Title
The small airway reaction to provocation with adenosine, reflected by the IOS parameter R5-R20
Description
The R5-R20 is measured with the IOS. This a method to determine the resistance of the small airways. The R5-R20 is measured during each provocation test after each provocative step.
Time Frame
Small airway reaction is measured during each provocation test. The Visits will take place in a period of 6 weeks.
Secondary Outcome Measure Information:
Title
The total airway reaction to provocation with adenosine, reflected by the decline in FEV1 (PD20/ PC20 values)
Description
We want to compare the different PD20/PC20 values of the three dry powder adenosine provocation test and with the nebulized AMP provocation test. The lung function is measured after each provocative step to determine the point of 20% decline in FEV1. The provocation test is ended after the last step or is ended prematurely when there is a 20% fall of FEV1 compared to baseline
Time Frame
Lung function is measured during each provocation test. All visits take place in a period of 6 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A doctor's diagnosis of asthma
Age: 18-65 years
PC20 AMP < 320 mg/ml
Non-smoker
Steroid naive or steroids have been stopped 4 weeks before entry into the baseline period
Exclusion Criteria:
Recent exacerbation asthma (<2 months) or upper respiration tract infection (<2 weeks)
Severe airway obstruction at baseline, FEV1pred< 50% or < 1.2L
Diagnosis of COPD or any other pulmonary disease that could influence the study results as judged by the investigator
Pregnancy or lactating women. (i.e. women of childbearing potential who do not use adequate anticonception as judged by the investigator).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nick ten Hacken, MD, Phd
Organizational Affiliation
University Medical Center Groningen
Official's Role
Study Chair
Facility Information:
Facility Name
University Medical Center Groningen
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
Facility Name
University Medical Center Groningen
City
Groningen
ZIP/Postal Code
9700RB
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Determining the Optimal Adenosine Provocation Test
We'll reach out to this number within 24 hrs